A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
Status:
Completed
Trial end date:
2020-06-26
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the safety, tolerability, and efficacy of
pembrolizumab (MK-3475, KEYTRUDA®) and pembrolizumab in combination with lenalidomide (Cohort
5 only) in hematologic malignancies. The primary study hypotheses are that treatment with
pembrolizumab will result in a clinically meaningful improvement in Objective Response Rate
(ORR) or Complete Remission Rate (CRR).
The study includes an initial dose determination to establish the recommended phase 2 dose
(RP2D) of lenalidomide given in combination with pembrolizumab in Cohort 5.
With Protocol Amendment 08, enrollment in the Multiple Myeloma arm (Cohort 2) has been
completed and no further enrollment will be allowed and enrollment in the Non-Hodgkin
Lymphoma Diffuse Large B Cell Lymphoma arm (Cohort 5) has been discontinued and no further
enrollment will be allowed.